Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:52:39.779Z.
Calculation as of: 2026-10-06T18:52:39.779Z.
Quote observation: 2026-10-06T18:50:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23d17170dcd90d56222e16e6e1c46ca5d6e49f0f5e08d353dc7d5f06f7b1586d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$9.62B
Price/FCF Ratio
37.32
TTM Avg
41.45
3Y Avg
45.70
5Y Avg
45.70
Market Cap
$9.21B
Price/FCF Ratio
98.11
TTM Avg
132.35
3Y Avg
74.15
5Y Avg
69.02
Market Cap
$9.98B
Price/FCF Ratio
28.25
TTM Avg
23.65
3Y Avg
33.40
5Y Avg
46.71
Market Cap
$10.05B
Price/FCF Ratio
90.76
TTM Avg
79.40
3Y Avg
81.24
5Y Avg
180.79
Market Cap
$10.06B
Price/FCF Ratio
24.01
TTM Avg
30.62
3Y Avg
33.44
5Y Avg
29.54
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | $9.42B | N/A | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.38B | 31.43 | 39.52 | 71.17 | 71.17 |
| Krystal Biotech, Inc. (KRYS)vs › | $9.62B | 37.32 | 41.45 | 45.70 | 45.70 |
| Henry Schein, Inc. (HSIC)vs › | $9.65B | 17.91 | 20.79 | 20.36 | 19.71 |
| Bruker Corporation (BRKR)vs › | $9.21B | 98.11 | 132.35 | 74.15 | 69.02 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.98B | 28.25 | 23.65 | 33.40 | 46.71 |
| Axsome Therapeutics, Inc. (AXSM)vs › | $9.01B | N/A | N/A | N/A | N/A |
| Repligen Corporation (RGEN)vs › | $10.05B | 90.76 | 79.40 | 81.24 | 180.79 |
| The Ensign Group, Inc. (ENSG)vs › | $10.06B | 24.01 | 30.62 | 33.44 | 29.54 |
| Bruker Corporation (BRKRP)vs › | $8.91B | 94.94 | 1012.95 | 992.25 | 992.25 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
